Treatment of Dementia with Lewy Bodies with Cognitive Decline

In patients with Dementia with Lewy bodies (DLB), cognitive decline and cognitive impairment are among the most clinically significant manifestations. Addressing these symptoms requires a focused, evidence-based approach that targets cognition, global function, and everyday ability.

Clinical Scenario This protocol applies to patients with Dementia with Lewy bodies presenting with cognitive decline or cognitive impairment. Treatment in DLB is focused on the cognitive, psychiatric, motor, and other nonmotor symptoms that represent the core or most common features of the disorder.

Treatment Approach (partial summary) The treatment approach involves a specific class of pharmacological agent with established evidence for improving cognitive symptoms in DLB — the full regimen, options, and clinical algorithm are available in the complete protocol.

Treatment Goals Improvement in cognition, global function, and activities of daily living.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1212/WNL.0000000000004058

Treatment of DLB is focused on the cognitive, psychiatric, motor, and other nonmotor symptoms that represent the core or most common features of the disorder.

Meta-analyses of Class I clinical trials of rivastigmine and donepezil support the use of cholinesterase inhibitors (CHEIs) in DLB for improving cognition, global function, and activities of living, with evidence that even if patients do not improve with CHEIs they are less likely to deteriorate while taking them.

View source ↗